1. Schadendorf, D., et al., Melanoma. Lancet, 2018. 392(10151): p. 971-984.
2. Luke, J.J., et al., Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol, 2017. 14(8): p. 463-482.
3. Spill, F., et al., Impact of the physical microenvironment on tumor progression and metastasis. Curr Opin Biotechnol, 2016. 40: p. 41-48.
4. Hinshaw, D.C. and L.A. Shevde, The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Res, 2019. 79(18): p. 4557-4566.
5. Cheetham, S.W., G.J. Faulkner, and M.E. Dinger, Overcoming challenges and dogmas to understand the functions of pseudogenes. Nat Rev Genet, 2020. 21(3): p. 191-201.
6. Jacq, C., J.R. Miller, and G.G. Brownlee, A pseudogene structure in 5S DNA of Xenopus laevis. Cell, 1977. 12(1): p. 109-20.
7. Xiao-Jie, L., et al., Pseudogene in cancer: real functions and promising signature. J Med Genet, 2015. 52(1): p. 17-24.
8. Mayer, W.E., C. O'HUigin, and J. Klein, Resolution of the HLA-DRB6 puzzle: a case of grafting a de novo-generated exon on an existing gene. Proc Natl Acad Sci U S A, 1993. 90(22): p. 10720-4.
9. Letca, A.F., et al., Regression and Sentinel Lymph Node Status in Melanoma Progression. Med Sci Monit, 2018. 24: p. 1359-1365.
10. de Moll, E.H., et al., Immune biomarkers are more accurate in prediction of survival in ulcerated than in non-ulcerated primary melanomas. Cancer Immunol Immunother, 2015. 64(9): p. 1193-203.
11. Zhang, Q., et al., Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma. Cell, 2019. 179(4): p. 829-845.e20.
12. William, M., et al., Translational repression of Ccl5 and Cxcl10 by 4E-BP1 and 4E-BP2 restrains the ability of mouse macrophages to induce migration of activated T cells. Eur J Immunol, 2019. 49(8): p. 1200-1212.
13. Hart, M., et al., Wrinkle in the plan: miR-34a-5p impacts chemokine signaling by modulating CXCL10/CXCL11/CXCR3-axis in CD4(+), CD8(+) T cells, and M1 macrophages. J Immunother Cancer, 2020. 8(2).
14. Glenfield, C. and A. McLysaght, Pseudogenes Provide Evolutionary Evidence for the Competitive Endogenous RNA Hypothesis. Mol Biol Evol, 2018. 35(12): p. 2886-2899.
15. Tomita, K., et al., Mixed Lineage Kinase 3 Mediates the Induction of CXCL10 by a STAT1-Dependent Mechanism During Hepatocyte Lipotoxicity. J Cell Biochem, 2017. 118(10): p. 3249-3259.
16. Aota, K., et al., Cepharanthine Inhibits IFN-gamma-Induced CXCL10 by Suppressing the JAK2/STAT1 Signal Pathway in Human Salivary Gland Ductal Cells. Inflammation, 2018. 41(1): p. 50-58.
17. Huang, L., et al., Key candidate genes of STAT1 and CXCL10 in melanoma identified by integrated bioinformatical analysis. IUBMB Life, 2019. 71(10): p. 1634-1644.
18. Burke, S.J., et al., Synergistic expression of the CXCL10 gene in response to IL-1beta and IFN-gamma involves NF-kappaB, phosphorylation of STAT1 at Tyr701, and acetylation of histones H3 and H4. J Immunol, 2013. 191(1): p. 323-36.
19. Mendez-Samperio, P., A. Perez, and L. Rivera, Mycobacterium bovis Bacillus Calmette-Guerin (BCG)-induced activation of PI3K/Akt and NF-kB signaling pathways regulates expression of CXCL10 in epithelial cells. Cell Immunol, 2009. 256(1-2): p. 12-8.
20. Hudy, M.H., S.L. Traves, and D. Proud, Transcriptional and epigenetic modulation of human rhinovirus-induced CXCL10 production by cigarette smoke. Am J Respir Cell Mol Biol, 2014. 50(3): p. 571-82.
21. Zhou, H., et al., CXCL10/CXCR3 axis promotes the invasion of gastric cancer via PI3K/AKT pathway-dependent MMPs production. Biomed Pharmacother, 2016. 82: p. 479-88.
22. Anichini, A., Progress in Understanding Complexity and Determinants of Immune-Related Prognostic Subsets in Primary Melanoma. Cancer Res, 2019. 79(10): p. 2457-2459.
23. Taylor, R.C., et al., Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol, 2007. 25(7): p. 869-75.
24. Bogunovic, D., et al., Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci U S A, 2009. 106(48): p. 20429-34.
25. Genomic Classification of Cutaneous Melanoma. Cell, 2015. 161(7): p. 1681-96.
26. Sade-Feldman, M., et al., Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell, 2018. 175(4): p. 998-1013.e20.
27. Lin, W.M. and D.E. Fisher, Signaling and Immune Regulation in Melanoma Development and Responses to Therapy. Annu Rev Pathol, 2017. 12: p. 75-102.
28. Chiang, J.J., et al., Viral unmasking of cellular 5S rRNA pseudogene transcripts induces RIG-I-mediated immunity. Nat Immunol, 2018. 19(1): p. 53-62.
29. Lee, S.M., et al., Toll-like receptor 10 is involved in induction of innate immune responses to influenza virus infection. Proc Natl Acad Sci U S A, 2014. 111(10): p. 3793-8.
30. Guo, S., et al., Genome-wide DNA methylation patterns in CD4+ T cells from Chinese Han patients with rheumatoid arthritis. Mod Rheumatol, 2017. 27(3): p. 441-447.
31. Lou, W., B. Ding, and P. Fu, Pseudogene-Derived lncRNAs and Their miRNA Sponging Mechanism in Human Cancer. Front Cell Dev Biol, 2020. 8: p. 85.
32. Ebert, M.S. and P.A. Sharp, Emerging roles for natural microRNA sponges. Curr Biol, 2010. 20(19): p. R858-61.
33. Wee, L.M., et al., Argonaute divides its RNA guide into domains with distinct functions and RNA-binding properties. Cell, 2012. 151(5): p. 1055-67.
34. Mauldin, I.S., et al., TLR2/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10. Int J Cancer, 2015. 137(6): p. 1386-96.
35. Antonicelli, F., et al., CXCL10 reduces melanoma proliferation and invasiveness in vitro and in vivo. Br J Dermatol, 2011. 164(4): p. 720-8.
36. Ribas, A., et al., Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. Nat Med, 2019. 25(6): p. 936-940.
37. Sunshine, J.C., et al., PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison. Clin Cancer Res, 2017. 23(16): p. 4938-4944.
38. Friedlander, P., et al., Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab. J Immunother Cancer, 2017. 5(1): p. 67.
39. House, I.G., et al., Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade. Clin Cancer Res, 2020. 26(2): p. 487-504.
40. Tang, Z., et al., GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res, 2017. 45(W1): p. W98-w102.
41. Li, T., et al., TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res, 2017. 77(21): p. e108-e110.
42. Casper, J., et al., The UCSC Genome Browser database: 2018 update. Nucleic Acids Res, 2018. 46(D1): p. D762-d769.
43. Cao, Z., et al., The lncLocator: a subcellular localization predictor for long non-coding RNAs based on a stacked ensemble classifier. Bioinformatics, 2018. 34(13): p. 2185-2194.
44. Li, J.H., et al., starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res, 2014. 42(Database issue): p. D92-7.